Soluble E-cadherin drives brain metastasis in aggressive inflammatory breast cancer

Soluble E-cadherin drives brain metastasis in aggressive inflammatory breast cancer

Researchers at The University of Texas MD Anderson Cancer Center have identified a targetable driver of brain metastases in patients with aggressive inflammatory breast cancer.

Blood Biomarker Points to Increased Risk of Brain Metastasis in Patients with Inflammatory Breast Cancer

* Brain metastases are a common complication of inflammatory breast cancer * High levels of soluble E-cadherin in the blood are associated with increased brain metastasis in these patients * A CXCR2 inhibitor reduced metastasis and improved survival in preclinical models, suggesting that targeting this pathway could prevent or treat brain metastasis